NDA 208462 · Takeda Pharms USA
Ninlaro
Ixazomib Citrate · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 20, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
155
13 Phase 3, 5 recruiting
FAERS reports
28,726
21,353 serious, 5,294 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 11, 2026.
NINLARO ® is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. ( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials. ( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials [see Warnings and Precautions (5.9) and Clinical Studies (14.2 , 14.3) ] .
Mechanism: Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome. Ixazomib induced apoptosis of multiple myeloma cell lines in vitro. Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines. In vivo, ixazomib demonstrated antitumor activity in a mouse...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 28, 2022 Supplement 12 · Efficacy OrphanLabel
- Nov 20, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
3 products under this application
- NINLARO · IXAZOMIB CITRATE EQ 2.3MG BASE · CAPSULE, ORAL · Prescription
- NINLARO · IXAZOMIB CITRATE EQ 3MG BASE · CAPSULE, ORAL · Prescription
- NINLARO · IXAZOMIB CITRATE EQ 4MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ixazomib" as an intervention, any sponsor and status, largest first.
- Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT03720041 · 740 participants (planned) · Start Aug 4, 2020 · Primary completion Dec 2024
Drug: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm; R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm and 2 more · For: Multiple Myeloma
Sites: Aberdeen, United Kingdom; Abergavenny, United Kingdom; Appley Bridge, United Kingdom · 110 sites in all
- A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT01564537 · 722 participants · Start Aug 1, 2012 · Primary completion Oct 1, 2014
Drug: Ixazomib; Lenalidomide and 2 more · For: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Sites: Little Rock, Arkansas; Anaheim, California; Berkeley, California · 24 sites in all
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02312258 · 706 participants · Start Apr 9, 2015 · Primary completion Aug 12, 2019
Drug: Placebo; Ixazomib · For: Multiple Myeloma
Sites: Fountain Valley, California; Los Angeles, California; Oceanside, California · 275 sites in all
- IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01850524 · 705 participants · Start Apr 29, 2013 · Primary completion Dec 2, 2019
Drug: Ixazomib; Placebo and 2 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 147 sites in all
- A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02181413 · 656 participants · Start Jul 16, 2014 · Primary completion Apr 16, 2018
Drug: Ixazomib Citrate; Placebo · For: Multiple Myeloma; Autologous Stem Cell Transplant
Sites: Little Rock, Arkansas; Rochester, Minnesota; The Bronx, New York · 227 sites in all
- Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.Pivotal-lookingStatus unknown
RenJi HospitalAcademic, hospital or other
NCT05477797 · 420 participants (planned) · Start Feb 16, 2023 · Primary completion Jan 15, 2026
Drug: Ixazomib DX/Lenalidomide DX · For: Progression Free Survival; Overall Survival; Maintenance
Sites: Shanghai, China
- The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)Pivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT03562169 · 406 participants (planned) · Start Mar 20, 2017 · Primary completion Mar 2026
Drug: Ixazomib, thalidomide, & dexamethasone (ITD) re-induction; Conventional autologous stem cell transplant (ASCT-con) and 2 more · For: Multiple Myeloma
Sites: Aberdeen, United Kingdom; Airdrie, United Kingdom; Ayr, United Kingdom · 91 sites in all
- Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraPivotal-lookingActive, not recruiting
European Myeloma Network B.V.Research network
NCT03896737 · 401 participants · Start Apr 16, 2019 · Primary completion Jun 30, 2026
Drug: Daratumumab plus Velcade Cyclophosphamide Dexamethasone; Velcade Thalidomide Dexamethasone · For: Multiple Myeloma
Sites: Hradec Králové, Czechia; Olomouc, Czechia; Ostrava, Czechia · 24 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma3,689
- death3,317
- diarrhoea3,163
- off label use2,976
- pneumonia1,937
- fatigue1,921
- nausea1,847
- neuropathy peripheral1,454
- vomiting1,110
- rash1,089
- thrombocytopenia1,050
- platelet count decreased1,008
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 63 |
| 2016 | 1,879 |
| 2017 | 2,393 |
| 2018 | 3,382 |
| 2019 | 4,438 |
| 2020 | 4,066 |
| 2021 | 4,533 |
| 2022 | 2,966 |
| 2023 | 1,976 |
| 2024 | 1,630 |
| 2025 | 1,042 |
| 2026 | 354 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ninlaro (Ixazomib Citrate)
2024 spending
$273M
Beneficiaries
2,983
21,413 claims
Per beneficiary
$91,419
$4,263.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $378,740,491 |
| 2021 | $366,333,436 |
| 2022 | $340,652,030 |
| 2023 | $311,982,549 |
| 2024 | $272,703,342 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M, Patel K, Eliason L, et al. · Lancet Haematol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Adjusting for subsequent therapies in the TOURMALINE-MM1 study shows clinically meaningful improvement in overall survival with addition of ixazomib to lenalidomide and dexamethasone.
Ramasamy K, Bahlis NJ, Kumar SK, et al. · Haematologica 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Rosiñol L, Oriol A, Ríos R, et al. · Blood 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
Dimopoulos MA, Sonneveld P, Leung N, et al. · J Clin Oncol 2016 · Pragmatic Clinical Trial
- Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T, Venner CP, Bahlis NJ, et al. · Blood 2021 · Multicenter Study, Randomized Controlled Trial
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P, Mateos MV, Berenson JR, et al. · Lancet Oncol 2018 · Clinical Trial, Phase III, Comparative Study
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.